Navigation Links
AstraZeneca and Targacept Announce Top-Line Results from Phase IIb Study of AZD3480 in Alzheimer's Disease
Date:9/15/2008

was a multi-center, randomized, double blind, placebo controlled, dose-finding study conducted at 84 sites in Western Europe, Eastern Europe and Canada. Subjects (n = 567) were between 60 and 85 years of age and diagnosed with probable Alzheimer's disease that was classified, based on a quantitative scale, as mild or moderate in severity. Subjects were assigned to one of three dose groups of AZD3480, to an active comparator, donepezil, or to placebo and dosed over 12 weeks. The primary outcome measure in the trial was change from baseline after 12 weeks on ADAS-Cog. A number of secondary outcome measures were also used in the trial.

About AstraZeneca

AstraZeneca is a major international healthcare business engaged in research, development, manufacturing and marketing of prescription pharmaceuticals and supplier for healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with healthcare sales of US $29.55 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection product sales. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

About Targacept

Targacept is a clinical-stage biopharmaceutical company that discovers and develops NNR Therapeutics (TM), a new class of drugs for the treatment of central nervous system diseases and disorders. Targacept's product candidates selectively modulate neuronal nicotinic receptors that serve as key regulators of the nervous system to promote therapeutic effects and limit adverse side effects. Targacept has product candidates in development for Alzheimer's disease, cognitive dysfunction in schizophrenia, pain and major depressive disorder, as well as multiple preclinical programs. Targacept also has a cognition-focused collaboration with AstraZeneca and a strategic alliance with GlaxoSmithKline. Targacept's news releases are available on its website at

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AstraZeneca Announces Innovative New Partnership With Singapore Institutions to Develop Anti-Cancer Compounds
2. AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
3. Phase III Study of Abbotts Investigational TriLipix(TM) in Combination With AstraZenecas CRESTOR(R) Meets Primary Endpoints on Key Lipids
4. AstraZeneca Submits sNDA for NEXIUM(R) I.V. for Peptic Ulcer Bleed Indication
5. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction
6. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
7. Volcano Announces Participation in SATURN Clinical Trial Sponsored by AstraZeneca
8. AstraZeneca Submits an sNDA for SYMBICORT(R) for COPD Indication
9. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
10. AstraZeneca Completes Enrollment in First Phase III Study of the Investigational Drug Vandetanib (ZACTIMA)(R) in Non-Small Cell Lung Cancer
11. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 2014 Legislation backed by the drugstore ... Pharmacies Act of 2014") championing so-called "any willing ... the availability of lower cost preferred pharmacy networks ... the next 10 years, according to new research ... Care Management Association (PCMA). The drugstore ...
(Date:7/22/2014)... , July 22, 2014  Eyeon Therapeutics has received ... treatment based on a charged hydrophilic polymer developed at ... has been shown to be safe and effective in ... MD, CEO states, "This first set of claims around ... way to moving this technology into the commercial phase.  ...
(Date:7/22/2014)... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and ... lots of Fluzone ® (Influenza Vaccine) for the 2014-2015 ... Food and Drug Administration (FDA) for distribution. The lots were ... least 65 million doses of seasonal influenza vaccine manufactured by ... providers and pharmacies in August. The U.S. ...
Breaking Medicine Technology:New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 2Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 3Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 4Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 5Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 6Sanofi Pasteur Begins Shipping Seasonal Influenza Vaccine for Upcoming 2014-2015 Season in United States 7
... Aug. 17 The hospital patient room of the future ... New Jersey, providing lessons that stand to benefit hospitals and ... building a new hospital in Plainsboro, NJ, to replace its ... a fully functioning replica of the new hospital,s proposed patient ...
... Inc. (NYSE Amex: ULU ) today announced its financial ... the second quarter of 2010, the Company reported a net loss of ... $2.9 million, or $0.04 per share, for the same period last year. ... net loss of $3.5 million, or $0.04 per share, compared with a ...
Cached Medicine Technology:Hospital Room of the Future Debuts in New Jersey 2Hospital Room of the Future Debuts in New Jersey 3Hospital Room of the Future Debuts in New Jersey 4ULURU Inc. Reports Second Quarter 2010 Financial Results 2ULURU Inc. Reports Second Quarter 2010 Financial Results 3ULURU Inc. Reports Second Quarter 2010 Financial Results 4ULURU Inc. Reports Second Quarter 2010 Financial Results 5ULURU Inc. Reports Second Quarter 2010 Financial Results 6
(Date:7/22/2014)... 22, 2014 Air Conditioning & Heating ... an authorized Daikin comfort pro dealer. This means that ... heating and cooling system equipment. Only a select few ... reviewed before being approved. , Daikin co-developed an R-410A ... Split System Air Conditioning Market. They are also the ...
(Date:7/22/2014)... 2014 United Benefit Advisors (UBA), the ... Les McPhearson, an insurance veteran with more than 15 ... and be based in the company's Chicago office. , ... that Les chose to accept this important, strategic position ... the many challenges facing UBA and its Partners as ...
(Date:7/22/2014)... By Steven Reinberg ... -- Women who are obese during pregnancy may be more ... new review suggests. "We found that, compared with children ... overweight or obese during pregnancy had up to 20 to ... Erick Forno, an assistant professor of pediatrics at Children,s Hospital ...
(Date:7/22/2014)... the Clean Plate Club you eat pretty much everything ... A new Cornell University study shows that the average adult ... or her plate. "If you put it on ... Ph.D., author of the forthcoming book, Slim by Design, Professor ... Lab. , Wansink and co-author Katherine Abowd Johnson analyzed 1179 ...
(Date:7/22/2014)... July 22, 2014 Legislation backed ... Access to Local Pharmacies Act of 2014”) championing ... D would undermine the availability of lower cost ... $21 billion over the next 10 years, according ... by the Pharmaceutical Care Management Association (PCMA). , ...
Breaking Medicine News(10 mins):Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 2Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 3Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 4Health News:Industry Leader Les McPhearson Joins United Benefit Advisors as New Chief Executive Officer 5Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 2Health News:Obesity During Pregnancy Linked to Raised Asthma Risk in Kids 3Health News:PCMA: New Study Finds H.R. 4577 to Cost $21 Billion Over 10 Years 2
... pretext for multinational corporations to take control of the precious ... With sales of over $35 billion worldwide in the ... buy up pristine springs in some of the country's most ... one-third of the U.S. market and sells 70 different brand ...
... overdose during pregnancy could be harmful, according to an Iranian ... combat anemia in pregnancy but many women take extra iron. ... carry enough oxygen due to low number of red blood ... carry normal amounts of oxygen. Common symptoms of anemia include ...
... for Inclusive Communities (CAIC) has recently joined the fight ... the majority of state and national disability rights organizations ... group that works on behalf of groups with developmental ... as a new national AP/Ipsis poll was released indicating ...
... the Pharmaceutical Research and Manufacturers of America (PhRMA) finds ... of the three leading causes of death of Americans ... currently in clinical trials or under review by the ... and stroke are still leading causes of death in ...
... advent of a possible new blockbuster drug and greater ... drug addictions, global sales of smoking cessation and ... little over $1.1 billion in 2005 to more than ... Addiction Treatments: A World Market Analysis, a new study ...
... on cardiometabolic risk factors beyond those expected from weight ... not be due to the drug itself, reports an ... Bulletin (DTB). ,Advertisements for rimonabant (sold ... an estimated 50% of the effects on cardiometabolic ...
Cached Medicine News:Health News:Multinationals Exploit Groundwater Sources, and People Suffer 2Health News:Multinationals Exploit Groundwater Sources, and People Suffer 3Health News:Multinationals Exploit Groundwater Sources, and People Suffer 4Health News:Multinationals Exploit Groundwater Sources, and People Suffer 5Health News:More Than 270 Medicines in Testing for Heart Disease and Stroke 2Health News:Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned 2
... matrix constructed of cross-linked collagen fibers ... through a proprietary 360 accretion process. ... aspirate, Healos provides an excellent environment ... differentiation. The hydroxyapatite-coated collagen microfibers in ...
Sharp Weitlaner Retractor....
Weitlaner retractor, blunt....
Bruns (Volkmann) bone curette, with Novotex plastic handle (autoclavable in autoclave up to 143C by 3 bar), 9, oval....
Medicine Products: